Literature DB >> 9269308

Enhanced radiosensitivity by inhibition of nuclear factor kappa B activation in human malignant glioma cells.

N Yamagishi1, J Miyakoshi, H Takebe.   

Abstract

To clarify the relationship between cellular radiosensitivity and nuclear factor kappa B (NF-kappa B) activation, an expression plasmid was constructed for I kappa B-alpha, a cellular inhibitory protein of NF-kappa B, and transfected it into two human malignant glioma cell lines. Cells overexpressing the I kappa B-alpha protein were more radiosensitive than the parental cells and one transfected clone with low expression. In the parental cell lines and one transfected clone with low expression, the sequence specific DNA-binding activity of NF-kappa B was considerably increased between 1 and 2 h after irradiation. In contrast, no increase in the DNA-binding activity was observed in the transfected clone overexpressing I kappa B-alpha protein. These results suggest that the activation of NF-kappa B may be one of the intrinsic responses determining cellular radiosensitivity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269308     DOI: 10.1080/095530097143374

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  18 in total

1.  Inhibition of cathepsin L sensitizes human glioma cells to ionizing radiation in vitro through NF-κB signaling pathway.

Authors:  Neng Yang; Pan Wang; Wen-juan Wang; Yun-zhen Song; Zhong-qin Liang
Journal:  Acta Pharmacol Sin       Date:  2015-02-09       Impact factor: 6.150

2.  Association of nuclear factor κB expression with a poor outcome in nasopharyngeal carcinoma.

Authors:  Y Zhang; J Y Lang; L Liu; J Wang; G Feng; Y Jiang; Y L Deng; X J Wang; Y H Yang; T Z Dai; G Xie; J Pu; X B Du
Journal:  Med Oncol       Date:  2010-05-25       Impact factor: 3.064

Review 3.  Targeting inflammatory pathways for tumor radiosensitization.

Authors:  Amit Deorukhkar; Sunil Krishnan
Journal:  Biochem Pharmacol       Date:  2010-06-30       Impact factor: 5.858

4.  Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity.

Authors:  Santosh K Sandur; Amit Deorukhkar; Manoj K Pandey; Ana María Pabón; Shujun Shentu; Sushovan Guha; Bharat B Aggarwal; Sunil Krishnan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-01       Impact factor: 7.038

5.  Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis.

Authors:  Chengyin Min; Yingshe Zhao; Mathilde Romagnoli; Philip C Trackman; Gail E Sonenshein; Kathrin H Kirsch
Journal:  J Cell Biochem       Date:  2010-12-01       Impact factor: 4.429

6.  Docosahexaenoic acid sensitizes Ramos cells to Gamma-irradiation-induced apoptosis through involvement of PPAR-gamma activation and NF-kappaB suppression.

Authors:  Hamid Zand; Ali Rahimipour; Saideh Salimi; Sayed Mohammad Shafiee
Journal:  Mol Cell Biochem       Date:  2008-06-20       Impact factor: 3.396

7.  Therapeutic strategies for head and neck cancer based on p53 status.

Authors:  Ichiro Ota; Noritomo Okamoto; Katsunari Yane; Akihisa Takahashi; Takashi Masui; Hiroshi Hosoi; Takeo Ohnishi
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

Review 8.  ATM-NF-kappaB connection as a target for tumor radiosensitization.

Authors:  Kazi Mokim Ahmed; Jian Jian Li
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

9.  Sensitization of tumor cells to cancer therapy by molecularly targeted inhibition of the inhibitor of nuclear factor κB kinase.

Authors:  Lijian Shao; Lixian Wu; Daohong Zhou
Journal:  Transl Cancer Res       Date:  2012-08       Impact factor: 1.241

10.  Expression of NF-κB p65 phosphorylated at serine-536 in rectal cancer with or without preoperative radiotherapy.

Authors:  Andreas Lewander; Jinfang Gao; Gunnar Adell; Hong Zhang; Xiao-Feng Sun
Journal:  Radiol Oncol       Date:  2011-09-22       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.